Biochemistry (Moscow)

, Volume 84, Issue 7, pp 695–710 | Cite as

The Role of Checkpoint Inhibitors and Cytokines in Adoptive Cell-Based Cancer Immunotherapy with Genetically Modified T Cells

  • P. M. GershovichEmail author
  • A. V. Karabelskii
  • A. B. Ulitin
  • R. A. Ivanov


This review focuses on the structure and molecular action mechanisms of chimeric antigen receptors (CARs) and major aspects of the manufacturing and clinical application of products for the CAR-T (CAR-modified T lymphocyte) therapy of hematological and solid tumors with special emphasis on the strategies for combined use of CAR-T therapy with immuno-oncological monoclonal antibodies (checkpoint inhibitors) and cytokines to boost survival, persistence, and anti-tumor efficacy of CAR-T therapy. The review also summarizes preclinical and clinical data on the additive effects of the combined use of CAR-T therapy with interleukins and monoclonal antibodies targeting immune checkpoints.


adoptive T cell immunotherapy of cancer chimeric antigen receptor CAR-T immuno-oncology immune checkpoint inhibitors cytokines interleukins 



chimeric antigen receptor


T cell expressing a chimeric antigen receptor






myeloid-derived suppressor cell


tumor-associated macrophage


transforming growth factor beta


regulatory T cell


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gross, G., Waks, T., and Eshhar, Z. (1989) Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity, Proc. Natl. Acad. Sci. USA, 86, 10024–10028.CrossRefGoogle Scholar
  2. 2.
    Fesnak, A. D., June, C. H., and Levine, B. L. (2016) Engineered T cells: the promise and challenges of cancer immunotherapy, Nat. Rev. Cancer, 16, 566–581, doi: 10.1038/nrc.2016.97.CrossRefGoogle Scholar
  3. 3.
    Li, J., Li, W., Huang, K., Zhang, Y., Kupfer, G., and Zhao, Q. (2018) Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward, J. Hematol. Oncol., 11, 22, doi: 10.1186/s13045-018-0568-6.CrossRefGoogle Scholar
  4. 4.
    Domschke, C., Schneeweiss, A., Stefanovic, S., Wallwiener, M., Heil, J., Rom, J., Sohn, C., and Schuetz, F. (2016) Cellular immune responses and immune escape mechanisms in breast cancer: determinants of immuno-therapy, Breast Care, 11, 102–107.CrossRefGoogle Scholar
  5. 5.
    Knochelmann, H. M., Smith, A. S., Dwyer, C. J., Wyatt, M. M., Mehrotra, S., and Paulos, C. M. (2018) CAR T cells in solid tumors: blueprints for building effective therapies, Front. Immunol., 9, 1–20, doi: 10.3389/fimmu.2018. 01740.CrossRefGoogle Scholar
  6. 6.
    Barrett, D. M., Singh, N., Porter, D. L., Grupp, S. A., and June, C. H. (2014) Chimeric antigen receptor therapy for cancer, Annu. Rev. Med., 65, 333–347, doi: 10.1146/ annurev-med-060512-150254.CrossRefGoogle Scholar
  7. 7.
    Sadelain, M., Brentjens, R., and Riviere, I. (2013) The basic principles of chimeric antigen receptor design, Cancer Discov., 3, 388–398, doi: 10.1158/2159-8290.CD-12-0548.CrossRefGoogle Scholar
  8. 8.
    Srivastava, S., and Riddell, S. R. (2015) Engineering CART cells: design concepts, Trends Immunol., 36, 494–502, doi: 10.1016/ Scholar
  9. 9.
    Gong, M. C., Latouche, J. B., Krause, A., Heston, W. D., Bander, N. H., and Sadelain, M. (1999) Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen, Neoplasia, 1, 123–127, doi: 10.1016/j.conbuildmat. 2013.02.024.CrossRefGoogle Scholar
  10. 10.
    Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers- Freezer, L., Chen, C. C., Yang, J. C., Rosenberg, S. A., and Hwu, P. (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer, Clin. Cancer Res., 12, 6106–6115, doi: 10.1158/1078-0432.CCR-06-1183.CrossRefGoogle Scholar
  11. 11.
    Lamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., and Oosterwijk, E. (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience, J. Clin. Oncol., 24, 20–22, doi: 10.1200/ JCO.2006.05.9964.CrossRefGoogle Scholar
  12. 12.
    Kowolik, C. M., Topp, M. S., Gonzalez, S., Pfeiffer, T., Olivares, S., Gonzalez, N., Smith, D. D., Forman, S. J., Jensen, M. C., and Cooper, L. J. N. (2006) CD28 costim-ulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells, Cancer Res., 66, 10995–11004, doi: 10.1158/0008-5472.CAN-06-0160.CrossRefGoogle Scholar
  13. 13.
    Brentjens, R. J., Santos, E., Nikhamin, Y., Yeh, R., Matsushita, M., La Perle, K., Quintas- Cardama, A., Larson, S. M., and Sadelain, M. (2007) Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts, Clin. Cancer Res., 13, 5426–5435, doi: 10.1158/1078-0432.CCR-07-0674.CrossRefGoogle Scholar
  14. 14.
    Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet- Desnoyers, G., Campana, D., Riley, J. L., Grupp, S. A., and June, C. H. (2009) Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo, Mol. Ther., 17, 1453–1464, doi: 10.1038/mt.2009.83.CrossRefGoogle Scholar
  15. 15.
    Chang, Z. L., and Chen, Y. Y. (2017) CARs: synthetic immunoreceptors for cancer therapy and beyond, Trends Mol. Med., 23, 430–450, doi: 10.1016/j.molmed.2017.03. 002.CrossRefGoogle Scholar
  16. 16.
    Sadelain, M. (2016) Chimeric antigen receptors: driving immunology towards synthetic biology, Curr. Opin. Immunol., 41, 68–76, doi: 10.1016/j.coi. 2016.06.004.CrossRefGoogle Scholar
  17. 17.
    Bridgeman, J. S., Ladell, K., Sheard, V. E., Miners, K., Hawkins, R. E., Price, D. A., and Gilham, D. E. (2014) CD3ζ-based chimeric antigen receptors mediate T cell activation via cis - and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy, Clin. Exp. Immunol., 175, 258–267, doi: 10.1111/cei.12216.CrossRefGoogle Scholar
  18. 18.
    Brentjens, R. J., Latouche, J.-B., Santos, E., Marti, F., Gong, M. C., Lyddane, C., King, P. D., Larson, S., Weiss, M., Riviere, I., and Sadelain, M. (2003) Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15, Nat. Med., 9, 279–286, doi: 10.1038/nm827.CrossRefGoogle Scholar
  19. 19.
    Schambach, A., and Morgan, M. (2016) Retroviral vectors for cancer gene therapy, in Current Strategies in Cancer Gene Therapy. Ser. Recent Results in Cancer Research ( Walther, W., ed.), Vol. 209, pp. 17–35, Springer, Cham, doi: 10.1007/978-3-319-42934-2_2.CrossRefGoogle Scholar
  20. 20.
    Scholler, J., Brady, T. L., Binder- Scholl, G., Hwang, W. T., Plesa, G., Hege, K. M., Vogel, A. N., Kalos, M., Riley, J. L., Deeks, S. G., Mitsuyasu, R. T., Bernstein, W. B., Aronson, N. E., Levine, B. L., Bushman, F. D., and June, C. H. (2012) Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells, Sci. Transl. Med., 4, 132ra53, doi: 10.1126/scitranslmed.3003761.Google Scholar
  21. 21.
    Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., Asnafi, V., MacIntyre, E., Dal Cortivo, L., Radford, I., Brousse, N., Sigaux, F., Moshous, D., Hauer, J., Borkhardt, A., Belohradsky, B. H., Wintergerst, U., Velez, M. C., Leiva, L., Sorensen, R., Wulffraat, N., Blanche, S., Bushman, F. D., Fischer, A., and Cavazzana-Calvo, M. (2008) Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1, J. Clin. Invest., 118, 3132–3142, doi: 10.1172/JCI35700.CrossRefGoogle Scholar
  22. 22.
    Brady, T., and Bushman, F. D. (2011) Nondividing cells: a safer bet for integrating vectors? Mol. Ther., 19, 640–641, doi: 10.1038/mt.2011.40.CrossRefGoogle Scholar
  23. 23.
    Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., and Trono, D. (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector, Science, 272, 263–267, doi: 10.1126/ science.272.5259.263.CrossRefGoogle Scholar
  24. 24.
    Levine, B. L., Miskin, J., Wonnacott, K., and Keir, C. (2017) Global manufacturing of CAR T cell therapy, Mol. Ther. Methods Clin. Dev., 4, 92–101, doi: 10.1016/j.omtm. 2016.12.006.CrossRefGoogle Scholar
  25. 25.
    Kebriaei, P., Singh, H., Huls, M. H., Figliola, M. J., Bassett, R., Olivares, S., Jena, B., Dawson, M. J., Kumaresan, P. R., Su, S., Maiti, S., Dai, J., Moriarity, B., Forget, M.-A., Senyukov, V., Orozco, A., Liu, T., McCarty, J., Jackson, R. N., Moyes, J. S., Rondon, G., Qazilbash, M., Ciurea, S., Alousi, A., Nieto, Y., Rezvani, K., Marin, D., Popat, U., Hosing, C., Shpall, E. J., Kantarjian, H., Keating, M., Wierda, W., Do, K. A., Largaespada, D. A., Lee, D. A., Hackett, P. B., Champlin, R. E., and Cooper, L. J. N. (2016) Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells, J. Clin. Invest., 126, 3363–3376, doi: 10.1172/JCI86721.CrossRefGoogle Scholar
  26. 26.
    Hackett, P. B., Aronovich, E. L., Hunter, D., Urness, M., Bell, J. B., Kass, S. J., Cooper, L. J. N., and McIvor, S. (2011) Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies, Curr. Gene Ther., 11, 341–349, doi: 10.2174/156652311797415827.CrossRefGoogle Scholar
  27. 27.
    Monjezi, R., Miskey, C., Gogishvili, T., Schleef, M., Schmeer, M., Einsele, H., Ivics, Z., and Hudecek, M. (2017) Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors, Leukemia, 31, 186–194, doi: 10.1038/leu.2016.180.CrossRefGoogle Scholar
  28. 28.
    Maude, S. L. (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia, N. Engl. J. Med., 371, 1507–1517, doi: 10.1056/NEJMoa1407222.CrossRefGoogle Scholar
  29. 29.
    Zhao, Z., Chen, Y., Francisco, N. M., Zhang, Y., and Wu, M. (2018) The application of CAR-T cell therapy in hema-tological malignancies: advantages and challenges, Acta Pharm. Sin. B, 8, 539–551, doi: 10.1016/j.apsb. 2018.03. 001.CrossRefGoogle Scholar
  30. 30.
    Wherry, E. J. (2011) T cell exhaustion, Nat. Immunol., 12, 492–499.CrossRefGoogle Scholar
  31. 31.
    McClanahan, F., Hanna, B., Miller, S., Clear, A. J., Lichter, P., Gribben, J. G., and Seiffert, M. (2015) PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lym-phocytic leukemia, Blood, 126, 203–211, doi: 10.1182/ blood-2015-01-622936.CrossRefGoogle Scholar
  32. 32.
    Iwai, Y., Hamanishi, J., Chamoto, K., and Honjo, T. (2017) Cancer immunotherapies targeting the PD-1 signaling pathway, J. Biomed. Sci., 24, 26, doi: 10.1186/s12929-017-0329-9.Google Scholar
  33. 33.
    Park, Y.-J., Kuen, D.-S., and Chung, Y. (2018) Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance, Exp. Mol. Med., 50, 109, doi: 10.1038/s12276-018-0130-1.CrossRefGoogle Scholar
  34. 34.
    Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler- Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., Raffeld, M., Feldman, S., Lu, L., Li, Y. F., Ngo, L. T., Goy, A., Feldman, T., Spaner, D. E., Wang, M. L., Chen, C. C., Kranick, S. M., Nath, A., Nathan, D.-A. N., Morton, K. E., Toomey, M. A., and Rosenberg, S. A. (2015) Chemotherapy-refractory diffuse large B-cell lym- phoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, J. Clin. Oncol., 33, 540–549, doi: 10.1200/JCO.2014.56.2025.CrossRefGoogle Scholar
  35. 35.
    Cherkassky, L., Morello, A., Villena- Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., and Adusumilli, P. S. (2016) Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition, J. Clin. Invest., 126, 3130–3144, doi: 10.1172/ JCI83092.CrossRefGoogle Scholar
  36. 36.
    Moon, E. K., Wang, L.-C., Dolfi, D. V., Wilson, C. B., Ranganathan, R., Sun, J., Kapoor, V., Scholler, J., Pure, E., Milone, M. C., June, C. H., Riley, J. L., Wherry, E. J., and Albelda, S. M. (2014) Multifactorial T-cell hypofunc-tion that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors, Clin. Cancer Res., 20, 4262–4273, doi: 10.1158/1078-0432.CCR-13-2627.CrossRefGoogle Scholar
  37. 37.
    Gargett, T., Yu, W., Dotti, G., Yvon, E. S., Christo, S. N., Hayball, J. D., Lewis, I. D., Brenner, M. K., and Brown, M. P. (2016) GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade, Mol. Ther., 24, 1135–1149, doi: 10.1038/mt. 2016.63.CrossRefGoogle Scholar
  38. 38.
    Brudno, J. N., Somerville, R. P. T., Shi, V., Rose, J. J., Halverson, D. C., Fowler, D. H., Gea- Banacloche, J. C., Pavletic, S. Z., Hickstein, D. D., Lu, T. L., Feldman, S. A., Iwamoto, A. T., Kurlander, R., Maric, I., Goy, A., Hansen, B. G., Wilder, J. S., Blacklock- Schuver, B., Hakim, F. T., Rosenberg, S. A., Gress, R. E., and Kochenderfer, J. N. (2016) Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell trans plantation without causing graft-versus-host disease, J. Clin. Oncol., 34, 1112–1121, doi: 10.1200/ JCO.2015.64.5929.CrossRefGoogle Scholar
  39. 39.
    John, L. B., Devaud, C., Duong, C. P. M., Yong, C. S., Beavis, P. A., Haynes, N. M., Chow, M. T., Smyth, M. J., Kershaw, M. H., and Darcy, P. K. (2013) Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells, Clin. Cancer Res., 19, 5636–5646, doi: 10.1158/1078-0432.CCR-13-0458.CrossRefGoogle Scholar
  40. 40.
    Li, S., Siriwon, N., Zhang, X., Yang, S., Jin, T., He, F., Kim, Y. J., Mac, J., Lu, Z., Wang, S., Han, X., and Wang, P. (2017) Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors, Clin. Cancer Res., 23, 6982–6992, doi: 10.1158/1078-0432.CCR-17-0867.CrossRefGoogle Scholar
  41. 41.
    Suarez, E. R., Chang, D. K., Sun, J., Sui, J., Freeman, G. J., Signoretti, S., Zhu, Q., and Marasco, W. A. (2016) Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model, Oncotarget, 7, 34341–34355, doi: 10.18632/oncotarget.9114.CrossRefGoogle Scholar
  42. 42.
    Maude, S. L., Hucks, G. E., Seif, A. E., Talekar, M. K., Teachey, D. T., Baniewicz, D., Callahan, C., Gonzalez, V., Nazimuddin, F., Gupta, M., Frey, N. V., Porter, D. L., Levine, B. L., Melenhorst, J. J., Lacey, S. F., June, C. H., and Grupp, S. A. (2017) The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL), J. Clin. Oncol., 35, 103–103, doi: 10.1200/JCO. 2017.35.15_suppl.103.CrossRefGoogle Scholar
  43. 43.
    Heczey, A., Louis, C. U., Savoldo, B., Dakhova, O., Durett, A., Grilley, B., Liu, H., Wu, M. F., Mei, Z., Gee, A., Mehta, B., Zhang, H., Mahmood, N., Tashiro, H., Heslop, H. E., Dotti, G., Rooney, C. M., and Brenner, M. K. (2017) CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neu-roblastoma, Mol. Ther., 25, 2214–2224, doi: 10.1016/ j.ymthe.2017.05.012.CrossRefGoogle Scholar
  44. 44.
    Anestakis, D., Petanidis, S., Kalyvas, S., Nday, C. M., Tsave, O., Kioseoglou, E., and Salifoglou, A. (2015) Mechanisms and applications of interleukins in cancer immunotherapy, Int. J. Mol. Sci., 16, 1691–1710, doi: 10.3390/ijms16011691.CrossRefGoogle Scholar
  45. 45.
    Belli, C., Trapani, D., Viale, G., D’ Amico, P., Duso, B. A., Della Vigna, P., Orsi, F., and Curigliano, G. (2018) Targeting the microenvironment in solid tumors, Cancer Treat. Rev., 65, 22–32, doi: 10.1016/j.ctrv.2018.02.004.CrossRefGoogle Scholar
  46. 46.
    Liu, D., and Zhao, J. (2018) Cytokine release syndrome: grading, modeling, and new therapy, J. Hematol. Oncol., 11, 121, doi: 10.1186/s13045-018-0653-x.Google Scholar
  47. 47.
    Sim, G. C., and Radvanyi, L. (2014) The IL-2 cytokine family in cancer immunotherapy, Cytokine Growth Factor Rev., 25, 377–390, doi: 10.1016/j.cytogfr.2014.07.018.CrossRefGoogle Scholar
  48. 48.
    Ahmadzadeh, M. (2006) IL-2 administration increases CD4+CD25hiFoxp3+ regulatory T cells in cancer patients, Blood, 107, 2409–2414, doi: 10.1182/blood-2005-06-2399.CrossRefGoogle Scholar
  49. 49.
    Appleman, L. J., Berezovskaya, A., Grass, I., and Boussiotis, V. A. (2000) CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression, J. Immunol., 164, 144–151, doi: Scholar
  50. 50.
    Mor, F., and Cohen, I. R. (1996) IL-2 rescues antigen-specific T cells from radiation or dexamethasone-induced apoptosis. Correlation with induction of Bcl-2, J. Immunol., 156, 515–522.Google Scholar
  51. 51.
    Zhang, X., Lv, X., and Song, Y. (2018) Short-term culture with IL-2 is beneficial for potent memory chimeric antigen receptor T cell production, Biochem. Biophys. Res. Commun., 495, 1833–1838, doi: 10.1016/j.bbrc.2017. 12.041.CrossRefGoogle Scholar
  52. 52.
    Brocker, T. (2000) Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T cells, Blood, 96, 1999–2001.Google Scholar
  53. 53.
    Emtage, P. C., Lo, A. S., Gomes, E. M., Liu, D. L., Gonzalo- Daganzo, R. M., and Junghans, R. P. (2008) Second generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation, Clin. Cancer Res., 14, 8112–8122, doi: 10.1158/1078-0432.CCR-07-4910.CrossRefGoogle Scholar
  54. 54.
    Lo, A. S., Ma, Q., Liu, D. L., and Junghans, R. P. (2010) Anti-GD3 chimeric sFv-CD28/T-cell receptor ζ designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors, Clin. Cancer Res., 16, 2769–2780, doi: 10.1158/1078-0432.CCR-10-0043.CrossRefGoogle Scholar
  55. 55.
    Forsberg, E. M., Lindberg, M. F., Jespersen, H., Alsen, S., Olofsson Bagge, R., Donia, M., Svane, I. M., Nilsson, O., Ny, L., Nilsson, L. M., and Nilsson, J. A. (2019) HER2 CAR-T cells eradicate uveal melanoma and T cell therapy-resistant human melanoma in interleukin-2 (IL-2) trans-genic NOD/SCID IL-2 receptor knockout mice, Cancer Res., 79, 899–904, doi: 10.1158/0008-5472.CAN-18-3158.CrossRefGoogle Scholar
  56. 56.
    Jensen, M. C., Popplewell, L., Cooper, L. J., DiGiusto, D., Kalos, M., Ostberg, J. R., and Forman, S. J. (2010) Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans, Biol. Blood Marrow Transplant., 16, 1245–1256, doi: 10.1016/j.bbmt.2010.03.014.CrossRefGoogle Scholar
  57. 57.
    Junghans, R. P., Ma, Q., Rathore, R., Gomes, E. M., Bais, A. J., Lo, A. S. Y., Abedi, M., Davies, R. A., Cabral, H. J., Al- Homsi, A. S., and Cohen, S. I. (2016) Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacody-namics as a determinant of clinical response, Prostate, 76, 1257–1270, doi: 10.1002/pros.23214.CrossRefGoogle Scholar
  58. 58.
    Wilkie, S., Burbridge, S. E., Chiapero- Stanke, L., Pereira, A. C. P., Cleary, S., van der Stegen, S. J. C., Spicer, J. F., Davies, D. M., and Maher, J. (2010) Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4, J. Biol. Chem., 285, 25538–25544, doi: 10.1074/jbc.M110.127951.CrossRefGoogle Scholar
  59. 59.
    Papa, S., van Schalkwyk, M., and Maher, J. (2015) Clinical evaluation of ErbB-targeted CAR T-cells, following intra-cavity delivery in patients with ErbB-expressing solid tumors, Methods Mol. Biol., 1317, 365–382, doi: 10.1007/ 978-1-4939-2727-2_21.CrossRefGoogle Scholar
  60. 60.
    Boyman, O., Purton, J. F., Surh, C. D., and Sprent, J. (2007) Cytokines and T-cell homeostasis, Curr. Opin. Immunol., 19, 320–326, doi: 10.1016/j.coi.2007.04.015.CrossRefGoogle Scholar
  61. 61.
    Xu, Y., Zhang, M., Ramos, C. A., Durett, A., Liu, E., Dakhova, O., Liu, H., Creighton, C. J., Gee, A. P., Heslop, H. E., Rooney, C. M., Savoldo, B., and Dotti, G. (2014) Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15, Blood, 123, 3750–3759, doi: 10.1182/blood-2014-01-552174.CrossRefGoogle Scholar
  62. 62.
    Gargett, T., and Brown, M. P. (2015) Different cytokine and stimulation conditions influence the expansion and immune phenotype of third generation chimeric antigen receptor T cells specific for tumor antigen GD2, Cytotherapy, 17, 487–495, doi: 10.1016/j.jcyt.2014.12.002.CrossRefGoogle Scholar
  63. 63.
    Casucci, M., Nicolis di Robilant, B., Falcone, L., Camisa, B., Norelli, M., Genovese, P., Gentner, B., Gullotta, F., Ponzoni, M., Bernardi, M., Marcatti, M., Saudemont, A., Bordignon, C., Savoldo, B., Ciceri, F., Naldini, L., Dotti, G., Bonini, C., and Bondanza, A. (2013) CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma, Blood, 122, 3461–3472, doi: 10.1016/j.jcyt.2014.12.002.CrossRefGoogle Scholar
  64. 64.
    Markley, J. C., and Sadelain, M. (2010) IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodefi-cient mice, Blood, 115, 3508–3519, doi: 10.1182/blood-2009-09-241398.CrossRefGoogle Scholar
  65. 65.
    Perna, S. K., Pagliara, D., Mahendravada, A., Liu, H., Brenner, M. K., Savoldo, B., and Dotti, G. (2014) Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition, Clin. Cancer Res., 20, 131–139, doi: 10.1158/1078-0432.CCR-13-1016.CrossRefGoogle Scholar
  66. 66.
    Trinchieri, G., Pflanz, S., and Kastelein, R. A. (2003) The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses, Immunity, 19, 641–644, doi: 10.1016/S1074-7613(03)00296-6.CrossRefGoogle Scholar
  67. 67.
    Trinchieri, G. (1998) Immunobiology of interleukin-12, Immunol. Res., 17, 269–278.CrossRefGoogle Scholar
  68. 68.
    Trinchieri, G. (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity, Nat. Rev. Immunol., 3, 133–146, doi: 10.1038/nri1001.CrossRefGoogle Scholar
  69. 69.
    Strasly, M., Cavallo, F., Geuna, M., Mitola, S., Colombo, M. P., Forni, G., and Bussolino, F. (2001) IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk, J. Immunol., 166, 3890–3899, doi: 10.4049/jimmunol.166.6.3890.CrossRefGoogle Scholar
  70. 70.
    Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., and Gately, M. K. (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors, J. Exp. Med., 178, 1223–1230, doi: 10.1084/jem.178.4.1223.CrossRefGoogle Scholar
  71. 71.
    Kalinski, P., Hilkens, C. M., Wierenga, E. A., and Kapsenberg, M. L. (1999) T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal, Immunol. Today, 20, 561–567, doi: 10.1016/S0167-5699(99)01547-9.CrossRefGoogle Scholar
  72. 72.
    Curtsinger, J. M., Lins, D. C., and Mescher, M. F. (2003) Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function, J. Exp. Med., 197, 1141–1151, doi: 10.1084/jem.20021910.CrossRefGoogle Scholar
  73. 73.
    Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., and Ryan, J. L. (1997) Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production, Blood, 90, 2541–2548.Google Scholar
  74. 74.
    Heinzerling, L., Burg, G., Dummer, R., Maier, T., Oberholzer, P. A., Schultz, J., Elzaouk, L., Pavlovic, J., and Moelling, K. (2005) Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy, Hum. Gene Ther., 16, 35–48, doi: 10.1089/hum.2005.16.35.CrossRefGoogle Scholar
  75. 75.
    Grabstein, K. H., Eisenman, J., Shanebeck, K., Rauch, C., Srinivasan, S., Fung, V., Beers, C., Richardson, J., Schoenborn, M. A., and Ahdieh, M. (1994) Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor, Science, 264, 965–968, doi: 10.1126/science.8178155.CrossRefGoogle Scholar
  76. 76.
    Carson, W. E., Giri, J. G., Lindemann, M. J., Linett, M. L., Ahdieh, M., Paxton, R., Anderson, D., Eisenmann, J., Grabstein, K., and Caligiuri, M. A. (1994) Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor, J. Exp. Med., 180, 1395–1403, doi: 10.1084/jem.180.4.1395.CrossRefGoogle Scholar
  77. 77.
    Yeku, O. O., and Brentjens, R. J. (2016) Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy, Biochem. Soc. Trans., 44, 412–418, doi: 10.1042/BST20150291.CrossRefGoogle Scholar
  78. 78.
    Marks-Konczalik, J., Dubois, S., Losi, J. M., Sabzevari, H., Yamada, N., Feigenbaum, L., Waldmann, T. A., and Tagaya, Y. (2000) IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice, Proc. Natl. Acad. Sci. USA, 97, 11445–11450, doi: 10.1073/ pnas.200363097.CrossRefGoogle Scholar
  79. 79.
    Jakobisiak, M., Golab, J., and Lasek, W. (2011) Interleukin 15 as a promising candidate for tumor immunotherapy, Cytokine Growth Factor Rev., 22, 99–108, doi: 10.1016/ j.cytogfr.2011.04.001.CrossRefGoogle Scholar
  80. 80.
    Ramanayake, S., Bilmon, I., Bishop, D., Dubosq, M.-C., Blyth, E., Clancy, L., Gottlieb, D., and Micklethwaite, K. (2015) Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials, Cytotherapy, 17, 1251–1267, doi: 10.1016/j.jcyt.2015.05.013.CrossRefGoogle Scholar
  81. 81.
    Numbenjapon, T., Serrano, L. M., Chang, W.-C., Forman, S. J., Jensen, M. C., and Cooper, L. J. N. (2007) Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells, Exp. Hematol., 35, 1083–1090, doi: 10.1016/j.exphem.2007.04.007.CrossRefGoogle Scholar
  82. 82.
    Nishio, N., and Dotti, G. (2015) Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors, Oncoimmunology, 4, e988098, doi: 10.4161/21505594.2014.988098.Google Scholar
  83. 83.
    Shenoy, A. R., Kirschnek, S., and Hacker, G. (2014) IL-15 regulates Bcl-2 family members Bim and Mcl-1 through JAK/STAT and PI3K/AKT pathways in T cells, Eur. J. Immunol., 44, 2500–2507, doi: 10.1002/eji.201344238.CrossRefGoogle Scholar
  84. 84.
    Spolski, R., and Leonard, W. J. (2014) Interleukin-21: a double-edged sword with therapeutic potential, Nat. Rev. Drug Discov., 13, 379–395, doi: 10.1038/nrd4296.CrossRefGoogle Scholar
  85. 85.
    Li, Y., and Yee, C. (2008) IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes, Blood, 111, 229–235, doi: 10.1182/blood-2007-05-089375.CrossRefGoogle Scholar
  86. 86.
    Alvarez-Fernandez, C., Escriba-Garcia, L., Vidal, S., Sierra, J., and Briones, J. (2016) A short CD3/CD28 cos-timulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy, J. Transl. Med., 14, 214, doi: 10.1186/s12967-016-0973-y.Google Scholar
  87. 87.
    Moroz, A., Eppolito, C., Li, Q., Tao, J., Clegg, C. H., and Shrikant, P. A. (2004) IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21, J. Immunol., 173, 900–909, doi: 10.4049/jimmunol.173.2.900.CrossRefGoogle Scholar
  88. 88.
    Hashmi, M. H., and Van Veldhuizen, P. J. (2010) Interleukin-21: updated review of phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin’s lymphoma, Expert Opin. Biol. Ther., 10, 807–817, doi: 10.1517/14712598.2010.480971.CrossRefGoogle Scholar
  89. 89.
    Singh, H., Figliola, M. J., Dawson, M. J., Huls, H., Olivares, S., Switzer, K., Mi, T., Maiti, S., Kebriaei, P., Lee, D. A., Champlin, R. E., and Cooper, L. J. N. (2011) Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies, Cancer Res., 71, 3516–3527, doi: 10.1158/0008-5472.CAN-10-3843.CrossRefGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2019

Authors and Affiliations

  • P. M. Gershovich
    • 1
    • 2
    Email author
  • A. V. Karabelskii
    • 1
    • 2
  • A. B. Ulitin
    • 1
  • R. A. Ivanov
    • 1
  1. 1.CJSC BiocadSt. PetersburgRussia
  2. 2.St. Petersburg State Chemical Pharmaceutical AcademySt. PetersburgRussia

Personalised recommendations